Sozinibercept, CAS 2568358-31-4

Product Description: Sozinibercept (OPT 302; VGX-300) is a soluble form of VEGFR-3, potently inhibits the activity of VEGF-C/D, which are the proangiogenic factors, inhibiting angiogenesis and vascular leakage. Sozinibercept also inhibits diabetic retinal edema in rats[1][2][3].

Applications: Neuroscience-Neuromodulation

Formula: N/A

References: [1]Turunen T, et al. VEGF-C and VEGF-D Inhibition by VGX-300 Effectively Reduces Leukocyte Adhesion and Vascular Leakage in the STZ-Rat Model of Diabetic Retinal Edema[J]. Investigative Ophthalmology & Visual Science, 2019, 60(9): 3667-3667. /[2]Lashkari K, et al. VGX-300, a ‘Trap’for VEGF-C and VEGF-D, Inhibits Choroidal Neovascularization and Vascular Leakage in a Mouse Model of Wet AMD[J]. Investigative Ophthalmology & Visual Science, 2015, 56(7): 4802-4802. /[3]Lashkari K, et al. VEGF-C and VEGF-D Blockade by VGX-300 Inhibits Choroidal Neovascularization and Leakage in a Mouse Model of wet AMD[J]. Investigative Ophthalmology & Visual Science, 2014, 55(13): 1823-1823.

CAS Number: 2568358-31-4

Molecular Weight: N/A

Compound Purity: 98.52

Research Area: Cardiovascular Disease

Solubility: 10 mM in DMSO

Target: VEGFR

• Artikelnummer: MEXHY-145633-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-145633-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK